curepsp-genetics-program

The CurePSP Genetics Program

Overview

The CurePSP Genetics Program (NCT06647641) is an active observational, prospective genetic study aiming to obtain DNA for research and clinical testing from patients with Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Multiple System Atrophy (MSA), and related neurological conditions, as well as their family members[@curepsp2024]. This landmark initiative represents one of the largest coordinated efforts to characterize the genetic architecture of the 4-repeat tauopathies, a group of neurodegenerative disorders characterized by the accumulation of abnormal tau protein in the brain.

The program is conducted by CurePSP, a nonprofit organization dedicated to advancing research, awareness, and care for PSP, CBS, MSA, and related disorders. Founded by patients and families affected by these conditions, CurePSP has become a leading force in funding research and facilitating collaboration among clinicians, scientists, and industry partners[@psporg].

Background: The Tauopathies

Progressive Supranuclear Palsy

Progressive supranuclear palsy is a rare but devastating neurodegenerative disorder that affects approximately 5-10 per 100,000 individuals[@nichols2022]. The disease is characterized by:

• Supranuclear gaze palsy: Difficulty moving eyes vertically, particularly downward
• Postural instability: Frequent falls, often backward
• Axial rigidity: Stiffness of the trunk and neck
• Cognitive decline: Executive dysfunction and behavioral changes

The CurePSP Genetics Program

Overview

The CurePSP Genetics Program (NCT06647641) is an active observational, prospective genetic study aiming to obtain DNA for research and clinical testing from patients with Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Multiple System Atrophy (MSA), and related neurological conditions, as well as their family members[@curepsp2024]. This landmark initiative represents one of the largest coordinated efforts to characterize the genetic architecture of the 4-repeat tauopathies, a group of neurodegenerative disorders characterized by the accumulation of abnormal tau protein in the brain.

The program is conducted by CurePSP, a nonprofit organization dedicated to advancing research, awareness, and care for PSP, CBS, MSA, and related disorders. Founded by patients and families affected by these conditions, CurePSP has become a leading force in funding research and facilitating collaboration among clinicians, scientists, and industry partners[@psporg].

Background: The Tauopathies

Progressive Supranuclear Palsy

Progressive supranuclear palsy is a rare but devastating neurodegenerative disorder that affects approximately 5-10 per 100,000 individuals[@nichols2022]. The disease is characterized by:

• Supranuclear gaze palsy: Difficulty moving eyes vertically, particularly downward
• Postural instability: Frequent falls, often backward
• Axial rigidity: Stiffness of the trunk and neck
• Cognitive decline: Executive dysfunction and behavioral changes

Corticobasal Syndrome

Corticobasal syndrome represents another 4-repeat tauopathy with distinct clinical features:

• Asymmetric rigidity: Often affecting one side of the body
• Apraxia: Difficulty performing learned motor tasks
• Alien limb phenomenon: Sense that a limb is foreign
• Cortical sensory loss: Impaired sensory discrimination

Multiple System Atrophy

Multiple system atrophy is a α-synucleinopathy that shares some clinical features with PSP and CBS:

• Autonomic dysfunction: Orthostatic hypotension, urinary dysfunction
• Cerebellar signs: Ataxia, nystagmus
• Parkinsonism: Bradykinesia, rigidity
• Pyramidal signs: Hyperreflexia, spasticity

Genetics of Tauopathies

The MAPT Gene

The microtubule-associated protein tau (MAPT) gene on chromosome 17q21 represents the most significant genetic risk factor for PSP and related tauopathies[@chen2024]:

H1 Haplotype:

• The H1 haplotype of MAPT is strongly associated with PSP risk
• H1/H1 genotype increases PSP risk approximately 5-8 fold
• This association has been confirmed in multiple populations worldwide

• Over 50 pathogenic MAPT mutations have been identified
• Mutations in the exon 10 splice site cause selective inclusion of 4R tau
• The P301L mutation is associated with familial frontotemporal dementia with parkinsonism (FTDP-17)

• Multiple single nucleotide polymorphisms (SNPs) in the MAPT region influence risk
• These variants are in linkage disequilibrium with the H1 haplotype
• Fine-mapping studies suggest regulatory variants as causal[@gromowska2024]

The C9orf72 Gene

Hexanucleotide repeat expansions in the C9orf72 gene are a common cause of familial ALS and frontotemporal dementia, and have also been implicated in PSP and CBS[@rodriguez2023]:

• Normal repeats: Up to 30 repeats
• Pathogenic repeats: Greater than 30-60 repeats (variable penetrance)
• Mechanisms: RNA foci formation, dipeptide repeat proteins, loss of function

The GRN Gene

Progranulin (GRN) mutations cause familial frontotemporal dementia and have been found in some CBS cases[@gao2024]:

• Inheritance: Autosomal dominant
• Mechanism: Loss-of-function leading to haploinsufficiency
• Phenotype: Variable age of onset (35-75 years), often with CBS or FTD

Other Genetic Loci

Genome-wide association studies (GWAS) have identified additional risk loci:

| Gene/Locus | Function | Odds Ratio in PSP |
|------------|----------|-------------------|
| MAPT | Tau protein | 5-8 (H1 haplotype) |
| MOBP | Myelin-associated oligodendrocyte protein | 1.5-2.0 |
| STX6 | Syntaxin 6 | 1.3-1.5 |
| SLCO1A2 | Solute carrier transporter | 1.3-1.5 |
| DUSP13 | Dual-specificity phosphatase | Protective |

These findings suggest that multiple pathways beyond tau metabolism contribute to disease susceptibility[@chen2019].

Study Design and Objectives

Primary Objectives

Secondary Objectives

• Genotype-phenotype correlations: Link genetic variants to clinical presentation and disease progression
• Biomarker development: Identify genetic biomarkers for diagnosis and clinical trial enrollment
• Population genetics: Characterize genetic diversity across different ancestry groups
• Resource creation: Build a genetic repository for the research community

Study Population

Inclusion Criteria:

• Clinical diagnosis of PSP, CBS, MSA, or related tauopathies
• Age 18 years or older
• Able to provide informed consent
• Willing to provide DNA sample and clinical information

• Unable to provide consent
• Known genetic cause other than tauopathy
• Previous enrollment in the program

• Any biological relative of an enrolled affected individual
• Willing to provide DNA sample
• Optional: Longitudinal clinical follow-up

Clinical Significance

Diagnostic Utility

The genetic information gathered through this program has significant diagnostic implications:

Confirmatory Testing:

• Identifies pathogenic variants in known tauopathy genes
• Enables predictive testing for at-risk family members
• Supports differential diagnosis between tauopathies and other neurodegenerative diseases

• Guides clinical subtype classification
• Informs prognosis based on specific mutations
• Helps distinguish sporadic from hereditary cases

Therapeutic Development

Genetic discoveries from this program will inform therapeutic development:

Drug Targets:

• MAPT haplotypes validate tau as a therapeutic target
• Novel variants reveal new biological pathways
• Genotype-stratified trials become possible

• Genetic stratification improves trial efficiency
• Biomarker development enables enrichment strategies
• Natural history studies inform endpoint selection

Genetic Counseling

The program provides important genetic counseling opportunities:

Family Planning:

• At-risk individuals can make informed decisions
• Reproductive options become available
• Multi-generational counseling supported

• Clarifies inheritance patterns
• Quantifies risk for different family members
• Addresses psychosocial implications

Research Methodology

Sample Collection

Standardized protocols ensure high-quality DNA for analysis:

• Primary sample type: Blood (EDTA tube)
• Alternative: Saliva (Oragene kit) for patients unable to provide blood
• Quantity: 10-20 mL blood or 2 mL saliva
• Processing: Centralized DNA extraction and storage

Genetic Analysis Pipeline

Tier 1 - Known Variants:

• Targeted genotyping of known pathogenic variants
• MAPT haplotype determination
• C9orf72 repeat sizing

• Whole-exome sequencing for novel variant discovery
• Bioinformatics filtering and annotation
• Pathogenicity prediction using multiple algorithms

• Whole-genome sequencing for structural variants
• Regulatory variant analysis
• Rare variant burden testing

Data Sharing and Privacy

Data Governance:

• De-identified data sharing with qualified researchers
• Controlled access through application process
• Annual data releases to the scientific community

• IRB-approved protocols protect participant privacy
• No individual-level data in public repositories
• Certificates of Confidentiality protect against compelled disclosure

Current Status and Enrollment

Trial Information

| Field | Value |
|-------|-------|
| NCT ID | NCT06647641 |
| Status | Recruiting |
| Enrollment Goal | Up to 1,000 adults |
| Start Date | 2024 |
| Estimated Completion | 2029 |
| Clinicaltrials.gov | [NCT06647641](https://clinicaltrials.gov/study/NCT06647641) |

Participating Sites

The program is implemented through a network of academic medical centers and clinical sites:

• Movement disorder clinics with PSP/CBS/MSA expertise
• Neurology departments with neurodegenerative disease programs
• Research institutions with tauopathy research focus

Participant Demographics

As the program progresses, enrollment demographics will be tracked:

• Age distribution across diagnostic categories
• Sex balance and ancestry diversity
• Family versus sporadic case proportions

Scientific Impact

Advancing Understanding of Tauopathies

The CurePSP Genetics Program addresses critical knowledge gaps:

Disease Mechanisms:

• How do specific genetic variants influence tau pathology?
• What are the molecular pathways from gene to disease?
• How do genetic backgrounds modify clinical phenotypes?

• What is the true proportion of hereditary tauopathy cases?
• How do environmental factors interact with genetic risk?
• What are the population-specific genetic architectures?

Building Research Infrastructure

The program creates lasting resources for the research community:

Biological Repository:

• DNA samples available for future studies
• Cell lines from selected participants
• Longitudinal sample collection

• Standardized clinical assessments
• Longitudinal follow-up data
• Natural history documentation

• Connections between researchers
• Data sharing infrastructure
• International coordination

Related Conditions

Overlap with Other Neurodegenerative Diseases

Genetic studies have revealed significant overlap between tauopathies and other conditions:

Alzheimer's Disease:

• Some PSP cases have comorbid amyloid pathology
• MAPT variants influence AD risk in some populations
• shared genetic factors between tauopathies and AD

• SNCA variants are risk factors for PD
• Some overlap in genetic susceptibility
• Different from typical PD genetics

• Shared GRN mutations
• Overlapping clinical presentations
• Common biological pathways

Implications for Related Disorders

The program's findings will inform research on:

• Chronic traumatic encephalopathy
• Pick's disease
• Primary age-related tauopathy
• Argyrophilic grain disease

Future Directions

Longitudinal Follow-Up

The program plans extended follow-up of participants:

• Annual clinical reassessments
• Tracking disease progression
• Correlation with genetic findings

Multi-Omics Integration

Future analyses will incorporate additional data types:

• Transcriptomic profiling: RNA sequencing to assess gene expression changes
• Proteomic analysis: Protein levels and post-translational modifications
• Metabolomic assessment: Metabolic biomarkers and pathway dysregulation
• Epigenetic modifications: DNA methylation and histone changes

International Collaboration

The program aims to coordinate globally:

• Data sharing: With international consortia (International PSP Genetics Consortium)
• Replication: In diverse populations across continents
• Coordinated analysis: Joint meta-analyses of genetic data

Historical Context and Program Development

Early Genetic Studies

The study of PSP genetics began in the 1990s with:

• Family studies documenting autosomal dominant inheritance in some cases
• Linkage analyses mapping the MAPT locus to chromosome 17q21
• Discovery of the H1 haplotype as the major genetic risk factor

Discovery of MAPT Mutations

The identification of pathogenic MAPT mutations represented a breakthrough:

• 1998: First MAPT mutations identified in familial frontotemporal dementia
• Subsequent years: Over 50 mutations catalogued across the tauopathy spectrum
• Today: Comprehensive mutation database informs clinical interpretation

Formation of CurePSP Initiative

The CurePSP Genetics Program emerged from:

• Recognition of the need for systematic genetic characterization
• Community advocacy for research funding
• Collaboration between academic centers and patient organizations

Ethical Considerations

Informed Consent

The program maintains rigorous ethical standards:

• Comprehensive consent forms explaining all procedures
• Ongoing consent updates as the program evolves
• Right to withdraw at any time without affecting care

Return of Results

Policies regarding genetic results are carefully considered:

• Clinical significance: Pathogenic variants with treatment implications may be returned
• Incidental findings: Policies align with ACMG recommendations
• Counseling support: Genetic counseling available for all participants

Data Ethics

Responsible data stewardship includes:

• Compliance with GDPR and other privacy regulations
• Regular ethics reviews and audits
• Community advisory board input

Clinical Integration

Genetic Testing in Practice

The program informs clinical genetic testing recommendations:

Testing Indications:

• Early onset PSP (<60 years)
• Family history of tauopathy or related conditions
• Unusual clinical presentations

• Sequential testing: MAPT → GRN → C9orf72 → other genes
• Panel testing: Multi-gene panels for differential diagnosis
• Whole-exome sequencing: When panel testing is unrevealing

Counseling Framework

Genetic counselors use program data to guide families:

• Risk communication: Clear explanation of inheritance patterns
• Decision support: Discussion of testing and reproductive options
• Psychosocial support: Resources for living with genetic risk

Economic Considerations

Cost-Effectiveness

Genetic testing provides economic benefits:

• Diagnostic odyssey reduction: Average cost savings of $5,000-15,000 per patient
• Avoidance of inappropriate treatments: Genetic diagnoses prevent futile therapies
• Family screening: Identification of at-risk individuals before symptoms

Resource Allocation

Program data inform healthcare resource planning:

• Testing infrastructure: Guide for laboratory capacity
• Counselor workforce: Identify training needs
• Research investment: Prioritize funding based on genetic findings

Future Research Directions

Gene-Specific Therapies

Genetic discoveries enable targeted therapeutic development:

• Antisense oligonucleotides: MAPT-targeted ASOs in development
• Gene therapy: Viral vector delivery of corrective genes
• Small molecule inhibitors: Tau aggregation inhibitors

Precision Medicine Approaches

Genotype-guided treatment strategies:

• Stratified clinical trials: Enriching for specific genetic backgrounds
• Personalized endpoints: Genotype-specific outcome measures
• Combination therapies: Targeting multiple genetic pathways

Prevention Studies

Genetic identification enables preventive interventions:

• Pre-symptomatic testing: Identifying at-risk individuals
• Early intervention: Initiating therapy before symptom onset
• Lifestyle modifications: Genetic risk-informed recommendations

Conclusion

The CurePSP Genetics Program represents a pivotal initiative in understanding the genetic basis of PSP, CBS, MSA, and related neurodegenerative disorders. By systematically collecting and analyzing genetic material from affected individuals and their families, the program will accelerate progress toward:

• Improved diagnostic accuracy
• Novel therapeutic targets
• Personalized medicine approaches
• Enhanced patient care

Related Pages

• [Genetics of PSP](/diseases/psp-genetics)
• [PSP Genetic Variants](/diseases/psp-genetic-variants)
• [MAPT Gene](/genes/mapt)
• [C9orf72 in CBS/PSP](/mechanisms/c9orf72-cbs-psp)
• [CurePSP Organization](/organizations/curepsp)
• [Tauopathies Overview](/diseases/tauopathies)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
• [Corticobasal Syndrome](/diseases/corticobasal-cbs)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy-msa)

External Links

• [CurePSP Official Website](https://www.psp.org/)
• [ClinicalTrials.gov - NCT06647641](https://clinicaltrials.gov/study/NCT06647641)
• [PubMed - Tauopathy Genetics](https://pubmed.ncbi.nlm.nih.gov/)
• [International PSP Genetics Consortium](https://www.psp.org/research)

References